Medical Radiology and Radiation Safety. 2026. Vol. 71. № 5

DOI:10.33266/1024-6177-2026-71-5-65-72

I.K. Khvostunov, V.V. Krylov, A.Yu. Shurinov, T.Yu. Kochetova, O.N. Korovchuk, A.S. Geraskina, S.A. Ivanov

EVALUATION OF RADIATION SAFETY OF RADIOPHARMACEUTICAL BASED ON 177LU-DOTA-PSMA IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER 

A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia

Contact person: Igor Khvostunov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

ABSTRACT

Purpose: To evaluate the safety and efficacy of radionuclide therapy with the radiopharmaceutical 177Lu-DOTA PSMA in patients with metastatic castration-resistant prostate cancer.

Material and methods: A total of 27 male patients with histologically confirmed metastatic prostate cancer and multiple metastatic lesions detected by positron emission tomography with high uptake of 18F-PSMA or 68Ga-PSMA were examined. The patients received radionuclide therapy with a single intravenous administration of the radiopharmaceutical 177Lu-DOTA-PSMA in subgroups with treatment activities ranging (0.637‒5.59), (6.81‒7.58), and (9.07‒10.5) GBq. To assess adverse radiation exposure, a biological dosimetry method based on the analysis of chromosome aberrations in blood lymphocytes was used. Peripheral blood samples were collected from the cubital vein before therapy and again after the administration of 177Lu-DOTA-PSMA. Chromosomal aberrations were analyzed using the standard metaphase method in cells in the first mitosis with cell incubation for 48 hours. The following chromosomal aberrations were analyzed: acentrics (ace: paired fragments and dots), centric rings (rc), and dicentrics (dic). The number of analyzed metaphases per patient ranged from 81 to 650, with an average of 314. A total of 21 563 metaphases in 68 blood samples were analyzed. Adverse radiation effects on the patient’s body were assessed based on the induction (increase) of chromosomal aberrations in blood lymphocytes, using a calibration dose curve previously obtained in our laboratory through in vitro experiments. Statistical processing of the results and regression analysis were performed using standard algorithms provided in Microsoft Excel and OriginLab.

Results: An increase in the mean frequency and median distribution for all three aberration combinations (ace+rc+dic), (rc+dic), and dic was found with increasing therapeutic activity of the administered radiopharmaceutical. The average adverse doses in subgroups were: 0.96±0.77 Gy in group I; 2.43±0.43 Gy in group II; and 2.69±0.36 Gy in group III, respectively. The average doses in subgroups II and III did not statistically differ from each other but significantly exceeded the dose in subgroup I (p<0.05). The dose coefficient for adverse radiation exposure to bone marrow in the examined patients was estimated to be within the range of (0.27–0.38) Gy/GBq. The average absorbed doses for individual patients exceeded the established safe limit of 2 Gy in 11.8% of patients in subgroup I, 44.4% in subgroup II, and 70% in subgroup III.

Conclusion: When treating patients diagnosed with metastatic castration-resistant prostate cancer with 177Lu-DOTA-PSMA, the absorbed dose in the red bone marrow may exceed the established safe limit of 2 Gy in a significant proportion of patients. The trend toward increased absorbed dose to the red bone marrow following administration of 177Lu-DOTA-PSMA, noted in recent years, is confirmed.

 

Keywords: metastatic castration-resistant prostate cancer, radioligand therapy, radiopharmaceutical drug, bone marrow, PET/CT, chromosomal aberrations

For citation: Khvostunov IK, Krylov VV, Shurinov AYu, Kochetova TYu, Korovchuk ON, Geraskina AS, Ivanov SA. Evaluation of Radiation Safety of Radiopharmaceutical Based on 177Lu-Dota-PSMA in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Medical Radiology and Radiation Safety. 2026;71(5):65–72. DOI:10.33266/1024-6177-2026-71-5-65-72

 

References

1.Bodei L., Herrmann K., Schoder H., et al. Radiotheranostics in Oncology: Current Challenges and Emerging Opportunities. Nat Rev Clinical Oncol. 2022;19;8:534–550. Doi: 10.1038/s41571-022-00652-y.

2.Gardner L.L., Thompson S.J., O’Connor J.D., McMahon S.J. Modelling Radiobiology. Physics in Medicine and Biology. 2024;69;18:18TR01. Doi: 10.1088/1361-6560/ad70f0.

3.Weber W.A., Czernin J., Anderson C.J., et al. The Future of Nuclear Medicine, Molecular Imaging and Theranostics. J Nucl Med. 2020;61;S2:263S–272S. Doi: 10.2967/jnmued.120.24532

4.Alsadi R., Djekidel M., Bouhali O., Doherty J.O. Towards Routine Clinical Use of Dosimetry in [177-Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives. Front. Phys. 2022;10:940677. Doi: 10.3389/fphy.2022.940677.

5.Yadav M.P., Ballal S., Sahoo R.K., et al. Long-Term Outcome of 177Lu-PSMA-617 Radioligand Therapy in Heavily Pre-Treated Metastatic Castration-Resistant Prostate Cancer Patients. PLoS One. 2021;16;5: e0251375. Doi: 10.1371/journal.pone.0251375.

6.Feuerecker B., Tauber R., Knorr K., et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration Resistant Prostate Cancer after Failure of Lutetium-177-PSMA. Eur Urology. 2021;79;3:343–350. Doi: 10.1016/j.eururo.2020.11.013.

7.Sundlöv A., Sjörgreen-Gleisner K., Svensson J., et al. Individualized 177-Lu-DOTATATE Treatment of Neuroendocrine Tumours Based on Kidney Dosimetry. EJNMMI. 2017;44;9:1480–1489. Doi: 10.1007/s00259-017-3678-4.

8.Cytogenetic Dosimetry: Applications in Preparedness for and Response to Radiation Emergencies. International Atomic Energy Agency. Vienna, IAEA, 2011. 247 p. 

9.Bolcaen J., Combrink N., Spoormans K., et al. Biodosimetry, Can It Fnd Its Way to the Nuclear Medicine Clinic?  Front Nucl Med. 2023;25;3:1209823. Doi: 10.3389/fnume.2023.1209823.

10.O’Neill E., Cornelissen B. Know Thy Tumour: Biomarkers to Improve Treatment of Molecular Radionuclide Therapy. Nucl Med Biol. 2022;108-109:44-53. Doi: 10.1016/j.nucmedbio.2022.02.004.

11.Wang Le, Bin Lu, Mengjie He, et al.  Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022;16;10:811044. Doi: 10.3389/fpubh.2022.811044. 

12.Состояние онкологической помощи населению России в 2024 году / Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. 275 с. [Sostoyaniye Onkologicheskoy Pomoshchi Naseleniyu Rossii v 2024 Godu = The State of Oncological Care for the Population of Russia in 2024. Ed. A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow, Moskovskiy Nauchno-Issledovatel’skiy Onkologicheskiy Institut im. P.A. Gertsena – filial FGBU «NMITS Radiologii» Minzdrava Rossii Publ., 2025. 275 p. (In Russ.)].

13.Hatano K.,  Nonomura N., Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: an Updated Review. World J Mens Health. 2023;41;4:769-784. Doi: 10.5534/wjmh.220200. 

14.Jackson P., Hofman M., McIntosh L., et al. Radiation Dosimetry in 177-Lu-PSMA-617 Therapy. Semin Nucl Med. 2022;52;2:243-254. Doi:10.1053/j.semnuclmed.2021.11.003.

15.Kratochwil C., Fendler W.P., Eiber M., et al. EANM Procedure Guidelines for Radionuclide Therapy with 177-Lu-Labelled PSMA-Ligands (177-Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46;12:2536-2544. Doi:10.1007/s00259-019-04485-3.

16.Khvostunov I.K., Saenko V.A., Krylov V.V., Rodichev A.A., Yamashita S. Cytogenetic Biodosimetry and Dose-Rate Effect after Radioiodine Therapy for Thyroid Cancer. Radiation and Environmental Biophysics. 2017;56;3:213-226. Doi: 10.1007/s00411-017-0696-3.

17.Khvostunov I.K., Nasonova E., Krylov V., et al. Cytogenetic Damage Induced by Radioiodine Therapy: a Follow-Up Case Study. Int J Mol Sci. 2023;24;6:5128. Doi: 10.3390/ijms24065128.

18.Севанькаев А.В., Хвостунов И.К., Снигирёва Г.П. и др. Сравнительный анализ результатов цитогенетических обследований контрольных групп лиц в различных отечественных лабораториях // Радиационная биология. Радиоэкология. 2013. Т.53. №1. С. 5–24 [Sevan’kayev A.V., Khvostunov I.K., Snigireva G.P., et al. Comparative Analysis of the Results of Cytogenetic Examinations of Control Groups of Individuals in Various Domestic Laboratories. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2013;53;1:5-24 (In Russ.)]. Doi: 10.7868/S0869803112060124.

19.Dale R.G. Radiation Repair Models for Clinical Application. Br J Radiol. 2019;92;1093:20180070. Doi: 10.1259/Bjr.20180070.

20.Bhat N.N., Rao B.S. Dose Rate Effect on Micronuclei Induction in Cytokinesis Blocked Human Peripheral Blood Lymphocytes. Radiat Prot Dos. 2003;106;1:45–52. Doi: 10.1093/oxfordjournals.rpd.a006333.

21.Kurth J., Krause B.J., Schwarzenböck S.M., et al. External Radiation Exposure, Excretion, and Effective Half-Life in 177-Lu-PSMA-Targeted Therapies. EJNMMI Research. 2018;8;1:32. Doi: 10.1186/s13550-018-0386-4.

22.Higueras M., González J.E., Di Giorgio M., Barquinero J.F. A Note on Poisson Goodness-of-Fit Tests for Ionizing Radiation Induced Chromosomal Aberration Samples. Int J Radiat Biol. 2018;94;7:656-663. Doi: 10.1080/09553002.2018.1478012.

23.Brill A.B., Stabin M., Bouville A., Ron E. Normal Organ Radiation Dosimetry and Associated Uncertainties in Nuclear Medicine, with Emphasis on Iodine-131. Radiat Res. 2006;66;1:128–140. Doi: 10.1667/RR3558.1.

24.Lassman M., Hanscheid H., Verburg F.A., Luster M. The Use of Dosimetry in the Treatment of Differentiated Thyroid Cancer. Q J Nucl Med Mol Imaging. 2011;55;2:107–115. PMID: 21386785.

25.Duong T.T., De Sarno D., Fakir H., et al. A Proof-of-Concept Study of Personalized Dosimetry for Targeted Radioligand Therapy Using Pre-Treatment Diagnostic Dynamic PET/ CT and Monte Carlo Simulation. Front Oncol. 2025;4;15:1600821. Doi: 10.3389/fonc.2025.1600821.

26.Водоватов А.В., Чипига Л.А., Петрякова А.В. и др. Методы дозиметрического планирования при проведении радионуклидной терапии. Часть 1: термины и определения // Лучевая диагностика и терапия. 2022. Т.13. №4. С. 9–15 [Vodovatov A.V., Chipiga L.A., Petryakova A.V., et al. Dosimetric Planning Methods for Radionuclide Therapy. Part 1: Terms and Definitions. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2022;13;4:9–15 (In Russ.)]. Doi: 10.22328/2079-5343-2022-13-4-9-15.

27.Kampen W.U., Boddenberg-Pätzold B., Fischer M., et al. The EANM Guideline for Radiosynoviorthesis. Eur J Nucl Med Mol Imaging. 2022;49;2:681-708. Doi: 10.1007/S00259-021-05541-7.

28.Klett R., Schnurbus-Duhs A., Mödder G., et al. Biological Dosimetry after Radiosynoviorthesis with Rhenium-186 Sulphide and Erbium-169 Citrate. Nuklearmedizin. 2012;51;1:17-25.  Doi: 10.3413/nukmed-0423-11-08.

29.Manil L., Voisin P., Aubert B., et al. Physical and Biological Dosimetry in Patients Undergoing Radiosynoviorthesis with Erbium-169 and Rhenium-186. Nuclear Med Comm. 2001;22;4:405–416. Doi: 10.1097/00006231-200104000-00009. 

30.Grmek M., Milcinski M., Fettich J., Brecelj J. Radiation Exposure of Hemophiliacs after Radiosynoviorthesis with 186-Re Colloid. Cancer Biother Radiopharm. 2007;22;3:417–422.

31.Хвостунов И.К., Крылов В.В., Петриев В.М., и др. Оценка радиационной безопасности радиофармпрепарата «Микросферы альбумина 5-10 мкм, меченые Re-188» при проведении радиосиновэктомии коленного сустава // Бюллетень Национального радиационно-эпидемиологического регистра. Радиация и риск. 2025. Т.34. №3. С.98-115. [Khvostunov I.K., Krylov V.V., Petriyev V.M., et al. Assessment of Radiation Safety of the Radiopharmaceutical “Albumin Microspheres 5-10 Μm, Labeled with Re-188” during Radiosynovectomy of the Knee Joint. Byulleten’ Natsional’nogo Radiatsionno-Epidemiologicheskogo Registra. Radiatsiya i Risk = Radiation and Risk. 2025;34;3:98-115 (In Russ.)]. Doi: 10.21870/0131-3878-2025-34-3-98-115.

32.Voth M., Klett R., Lengsfeld P. Biological Dosimetry after Yttrium-90 Citrate Colloid Radiosynoviorthesis (RSO). Nuklearmedizin. 2006;45;5:223-228. Doi: 10.1155/prm/8887391. eCollection 2025.

33.Lloyd D.C., Reeder E.J. Chromosome Aberrations and Intra-Articular Yttrium-90. The Lancet. 1978;311;8064:617. Doi: 10.1016/s0140-6736(78)91072-3.

34.Violot D., M’Kacher R., Adjadj E., et al. Evidence of Increased Chromosomal Abnormalities in French Polynesian Thyroid Cancer Patients. Eur. J. Nucl. Med. Mol. 2005;32;2:174–179. Doi: 10.1007/s00259-004-1662-2.

35.Kinashi Y., Sakurai Y., Masunaga S., et al. Evaluation of Micronucleus Induction in Lymphocytes of Patients Following Boron-Neutron-Capture-Therapy: a Comparison with Thyroid Cancer Patients Treated with Radioiodine. J Radiat Res. 2007;48;3:197–204. Doi: 10.1269/jrr.06086.

36.de Keizer B., Hoekstra A., Konijnenberg M.W. Bone Marrow Dosimetry and Safety of High 131-I Activities Given after Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2004;45;9:1549–1554. PMID: 15347723.

37.Fendler W.P., Reinhardt S., Ilhan H., et al. Preliminary Experience with Dosimetry, Response and Patient Reported Outcome after 177-Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer. Oncotarget. 2017;8:3581–3590. Doi: 10.18632/oncotarget.12240.

38.Feuerecker B., Chantadisai M., Allmann A., et al. Pretherapeutic Comparative Dosimetry of 177-Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63;6:833–839. Doi: 10.2967/jnumed.121.262671.

38.Gosewisch A., Ilhan H., Tattenberg S., et al. 3D Monte Carlo Bone Marrow Dosimetry for Lu-177-PSMA Therapy with Guidance of Non-Invasive 3D Localization of Active Bone Marrow Via Tc-99m-anti-Granulocyte Antibody SPECT/CT. EJNMMI Res. 2019;9;1:76. Doi: 10.1186/s13550-019-0548-z.

39.Gosewisch A., Delker A., Tattenberg S., et al. Patient-Specific Image-Based Bone Marrow Dosimetry in Lu-177-[DOTA0, Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 Therapy: Investigation of a New Hybrid Image Approach. EJNMMI Res. 2018;8;1:76. Doi: 10.1186/s13550-018-0427-z.

40.Robbins R.J., Schlumberger M.J. The Evolving role of 131-I for the Treatment of Differentiated Thyroid Carcinoma. J Nucl Med. 2005;46;Suppl 1: 28S-37S. PMID: 15653649.

41.Violet J., Jackson P., Ferdinandus J., et al. Dosimetry of 177-Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60;4:517–523. Doi: 10.2967/jnumed.118.219352.

42.Rosar F., Schön N., Bohnenberger H., et al. Comparison of Different Methods for Post-Therapeutic Dosimetry in [177-Lu]Lu-PSMA-617 Radioligand Therapy. EJNMMI Phys. 2021;8;1:40. Doi: 10.1186/s40658-021-00385-4.

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest.The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.04.2026. Accepted for publication: 25.05.2026.